2.27
+0(+0.00%)
Currency In USD
Address
4149 Liberty Canyon Road
Agoura Hills, CA 91301
United States of America
Phone
805-730-0360
Website
Sector
Healthcare
Industry
Biotechnology
Employees
83
First IPO Date
May 04, 2023
| Name | Title | Pay | Year Born |
| Mina Kim | Chief Executive Officer & Director | 906,640 | 1974 |
| Shephard Mpofu | Chief Medical Officer | 679,645 | 1967 |
| K. Amar Murugan | Chief Legal Officer | 0 | 1976 |
| Kenneth A. Lock | Chief Commercial Officer | 0 | 1974 |
| Tyler Marciniak | Vice President of Investor Relations, Communications & Corporate Operations | 0 | N/A |
| Kelly Chow | Chief People Officer | 0 | N/A |
| Patricia A. Turney | Chief Technical Operations Officer | 0 | 1967 |
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.